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The combined dyshormonal pathology of the uterus and mammary glands represents a great 
danger to the health of a woman, as well as impairs the quality of life, reduces the reproductive 
capacity of a woman and leads to premature loss of reproductive function. Steroid hormones 
play a large role in the regulation of proliferative changes in the uterus and mammary glands. 
Regulation of target organs, uterus and mammary glands, due to the presence of common mech-
anisms associated with the presence of the receptor apparatus in the tissues of these organs to sex 
hormones. The general links of pathogenesis and the high frequency of combined pathology of 
the uterus and mammary glands are of interest to study not only isolated forms of proliferation, 
but also the development of a unified systematic approach to the study of this pathology. In re-
cent times, there are opposing views on the role of hormonal dysfunction as a factor in prolifera-
tive processes. The management tactics of patients with pathological changes in the mammary 
gland in various gynecological diseases is an assessment of endocrine status, normalization of 
hormonal and metabolic disorders, especially when progesterone and cortisol are excreted, tes-
tosterone levels are increased, and hyperprolactinemia is affected. Special attention should be 
paid to patients with menstrual disorders, reproductive health disorders. We believe that the 
problem of the hyperproliferative processes of the uterus and mammary glands should not be 
considered only from the perspective of gynecological or mammological practice. This pathol-
ogy is polymorphic and should have broad interdisciplinary connections with such disciplines 
as oncology, endocrinology, gastroenterology, psychiatry, therapy, pathomorphology, histology, 
obstetrics and gynecology. Only by studying all possible links of etiopathogenesis, by combin-
ing interdisciplinary communication, it is possible to effectively fight for the quality of patients 
with a combined pathology of the uterus and mammary glands. Family planning, prevention of 
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unplanned pregnancy, timely implementation of maternity, prevention of miscarriage, the use of 
modern contraceptives, support for breastfeeding is also of high importance for the prevention 
of disorders and the preservation, extension of reproductive capabilities, and the prevention of 
combined dyshormonal pathology of the uterus and breast.
Keywords: hormonal status, mammary glands hyperplastic processes, endometrial hyperpla-
sia, uterine fibroids, fibrocystic disease of the breast, ovarian dysfunction, especially steroido-
genesis, women of reproductive age, hormonal dysfunction, hyperprolactinemia, proliferative 
breast disease, anovulation, gipoestrogeniya, hyperandrogenism, menstrual cycle.
Introduction
Some aspects of the pathogenesis of uterine fibroids and fibrocystic disease of the 
breast still remain an important issue for research by modern Russian and foreign authors 
[1; 2]. At the same time, significant progress in molecular genetics and biology makes it 
possible to identify genetic factors and initial molecular defects leading to the develop-
ment of proliferative changes in the uterus and mammary glands. It is known that benign 
diseases of the mammary glands in gynecological patients are most often found in cases 
of uterine fibroids, which is associated with the common pathogenesis and morphological 
processes occurring in the target organs: uterus and mammary glands [3].
The menstrual function and the processes occurring in the mammary glands are 
under the common neuroendocrine control of the hypothalamic-pituitary-ovarian and 
adrenal systems, as well as under the effect of the action of other endocrine glands and 
growth factors [3; 4]. Benign breast diseases are observed in 20–25 % of women under the 
age of 30, 60 % or more aged 40 and older, and these diseases are the background for the 
development of breast cancer [3]. 
It is proved that breast cancer occurs 3–5 times more often against the background 
of fibrocystic disease of the breast and 25–30 times more often in the presence of prolif-
erative processes, and it is the main component in the structure of cancer incidence [5]. 
According to the definition of the WHO, fibrocystic disease of the breast is a disease with 
an abnormal ratio of epithelial and connective tissue components and a wide spectrum of 
proliferative and regressive changes in the breast tissue [6]. During a woman’s reproduc-
tive years, her mammary gland often undergo proliferative and regressive changes in the 
epithelial and supporting tissues, which is associated with the phases of the menstrual 
cycle and, therefore, with different levels of sex hormones.
Improper regulation of these processes often leads to structural changes, which can 
be manifested in the form of diffuse and diffuse-nodal changes. The most common of 
them is fibrocystic disease of the breast [7].
It is known that 97.8 % of women of reproductive age with neuroendocrine gyneco-
logical diseases are found to have pathological alterations of mammary glands [3]. It is 
noted that in women with oligomenorrhea, breast lesions occur in 64.5 % of cases, and 
hyperplastic processes are observed 2 times more often than in the endometrium.
In patients with gynecological diseases accompanied by dysfunctional uterine bleed-
ing, concomitant diseases of mammary glands are found in 57.6 % of cases; in second-
ary amenorrhea, these are found in 43.6 % of the patients, and among women with poly-
cystic ovary syndrome, in 25 % of cases. The data obtained made it possible to develop 
a concept of the common pathogenesis of the mechanisms of the development of hor-
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mone-dependent hyperplastic diseases of female genital organs and mammary glands. 
Uterine fibroids are still one of the most frequent gynecological diseases. The incidence 
of this pathology reaches 20–30 % among women of reproductive age, and according to 
autopsy data, its prevalence is about 50–77 % [8; 9]. About 80 % of women in the age of 
perimenopause have a high risk of tumors. However, in the recent years, a trend for the 
younger onset of disease has been observed: often uterine fibroids are found in 20-year-
old patients, especially since the preclinical stage lasts on an average for 8–10 years, and 
preventive examinations result in the discovery of the tumor in 1–5 % of women, and 
small myomatous nodes are found at ultrasound examination in 20 % of women [10]. 
Risk factors for uterine fibroids are ethnicity, parity (the relative risk of uterine fi-
broids is reduced with the increase of the number of  deliveries in pregnancies reach-
ing viable gestational age and increases in women who had artificial abortions), being 
overweight, hereditary predisposition, concomitant inflammatory diseases of the genitals, 
endometriosis, intrauterine interventions [11].
Uterine fibroids have an adverse effect on the woman’s reproductive health. A fre-
quent complication of uterine fibroids is infertility. In recent years, there has been a clear 
increase in the frequency of the combination of uterine fibroids and pregnancy (from 
0.5 to 6 %). In most cases, pregnancy and childbirth in women with uterine fibroids are 
accompanied by frequent complications: threatening miscarriage, fetoplacental insuffi-
ciency, abnormal labor, hypotonic bleedings, subinvolution of the uterus, etc.
Often, uterine fibroids are combined with other hyperplastic processes of the repro-
ductive organs and mammary glands (endometriosis, endometrial hyperplasia, back-
ground diseases of the cervix and various forms of fibrocystic disease of the breast).
Particularly important among the risk factors for breast cancer are proliferative dis-
eases of the mammary glands, which are grouped by WHO experts under the term of 
fibrocystic disease of the breast.
In this regard, the College of American Pathologists recommends to divide women 
with fibrocystic disease of the breast into three categories [12; 13]:
 — non-proliferative fibrocystic disease or the disease with a light intraductal epithe-
lial proliferation. The risk of the development of infiltrating cancer is not increased 
and is at the same level as the risk in the general population;
 — fibrocystic disease with moderate intraductal epithelial proliferation. The risk of 
infiltrating breast cancer development is 1.5–2 times higher than the risk for the 
general population;
 — fibrocystic disease with atypical intraductal proliferation. The risk of infiltrating 
breast cancer is 5 times higher compared to the risk for the general population. 
The risk of breast cancer in patients with epithelial proliferation in the lumen of 
the glandular cavities is 14 times higher than in patients without such prolifera-
tion [14]. Histological examination revealed a combination of proliferative forms 
of fibrocystic disease of the breast and minimal breast cancer in 55–67 % of cases 
[15; 16]. Moreover, current data indicate a morphogenetic relationship between 
proliferative forms of fibrocystic disease of the breast and minimal breast cancer. 
Pechoux C., in the paper on the possible relationship between fibrocystic disease 
of the breast and breast cancer, stressed that sclerocystic mastitis (cystic disease 
of breast, Reclus’ disease, Schimmelbusch’s disease) refers to diseases that tend to 
malignize under certain conditions [17]. There is an opposite opinion, according 
126 Вестник СПбГУ. Медицина. 2019. Т. 14. Вып. 2
to which fibrocystic disease of the breast is a “functional0Ф estrogen-dependent 
state, which is capable of spontaneous regression in postmenopause. According to 
T. Gudjonsson, cystic changes in the mammary gland, in cases of individual cysts, 
regress in the first year after the termination of menses in 50 % of cases, and in the 
second year, in 73 % of cases. However, the author showed that in postmenopausal 
period of 5 years or more, positive dynamics is observed only in 12 % of patients 
with fibrocystic disease of the breast [18].
It is known that pathological conditions of the gastrointestinal tract which are as-
sociated not only with liver function disorders but also with intestinal function disorder, 
lead to reabsorption of steroid hormones. This results in the development of estrogen-de-
pendent diseases such as fibrocystic disease of the breast and breast cancer. These patients 
are recommended to undergo treatment and correction of gastrointestinal disorders by a 
gastroenterologist, to take adequate amount of fluids, up to 2 liters per day, and increased 
consumption of foods containing fiber [19].
The therapy method which must be considered the most nosotropic, taking into ac-
count the hormonal regulation of the mammary gland, is the use of hormonal agents. 
Oncologists, mammologists, gynecologists, and surgeons have accumulated data on the 
possibility of effective use of various hormonal methods of treatment of benign pathology 
of the mammary glands [6]. It should be noted that it is currently believed that a decisive 
role in the development of mammary glands diseases belongs to progesterone-deficient 
conditions, in which excess estrogen causes proliferation of breast tissue and the receptor 
apparatus disorder. 
Clinical practice confirms that the majority of patients with gynecological diseases, 
especially with dishormonal disorders, also have some mammary gland diseases. At the 
same time, the greatest risk of severe pathology of the mammary glands exists for women 
with hyperplastic processes of the genitals. The structure of breast pathology in patients 
with neuroendocrine genital pathology is as follows [20]:
1) hyperplastic diseases: 65.4 %;
2) premature involutive changes: 32.5 %;
3) nodal proliferative processes: 6.5 %.
The literature data indicate the relevance and necessity of studying the condition of 
the mammary gland, and a special emphasis must be made on the administration of the 
appropriate pathogenetically substantiated therapy of both gynecological diseases and 
breast pathology.
Goal of research: to study and evaluate the role of changes in the hypothalamic-
pituitary-ovarian system, taking into account the clinical features of patients with benign 
breast diseases, proliferative fibrocystic disease of the breast with hyperplastic processes of 
the uterus in the background, including the endometrium.
Materials and methods
To reach the stated goal, 350  women underwent medical tests and examinations. 
Three representative clinical groups of patients were formed. The first (1) group includ-
ed 150 patients with benign diseases of the mammary glands against the background of 
hyperplastic processes of the uterus, including the endometrium, the second (2) group 
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consisted of 50 patients with proliferative fibrocystic disease of the breast, and the third 
(3) (control) group included 150 patients with hyperplastic processes of the uterus not 
accompanied by breast diseases. 
The patients were selected for the group based on a copy-pair principle. The examined 
patients were from 20 to 40 years old. The past medical history of the examined women 
was studied according to the questionnaire we had developed. Special attention was paid 
to heredity, gynecological, mammal and oncological diseases in close relatives, as well as 
to extragenital diseases in the patient’s medical background. Also, copies of information 
were made from the primary medical records of the women, which made it possible to 
adjust the data of the survey. 
Measurements were taken of the women’s height, weight, waist, hips,  and the body 
mass index and the waist-to-hips ratio were calculated. The severity and nature of endo-
metrial pathology were determined with the use of transvaginal ultrasound, aspiration bi-
opsy of the endometrium, hysteroscopy with separate diagnostic curettage of the cervical 
canal and uterine mucosa, and cervical biopsy followed by histological examination ac-
cording to the generally accepted technique. All the women were examined by a therapist 
and consulted by a mammologist.
For examination of the mammary glands the following diagnostic methods were 
used: examination and palpation by conventional methods, mammography, ultrasound, 
morphological examination of biopsies.
The functional status of hypothalamic-pituitary-ovarian system and the adrenal 
function in the blood were studied with the use of  functional diagnostics (temperature 
test, the cervical pupil sign, the crystallization of mucus). The content of hormones in the 
blood (FSH — follicle stimulating hormone, LH — luteinizing, PRL — luteotropic (prol-
actin) hormones of the pituitary gland, E2 — estradiol, PG-progesterone) was determined 
by enzyme immunoassay method with the use of the generally accepted technique. The 
levels of 17-ketosteroids and 17 — oxycorticosteroids were determined according to gen-
erally accepted recommendations. 
The criteria for exclusion from the study were a body mass index of more than 30, the 
absence of independent menstruation, diabetes and hormonal therapy administration.
The statistical processing of the results was performed with the use of EXIL–
20G0 software. The significance of the differences was assessed with the use of Student’s t-
test, Pearson’s correlation coefficient and x2 criterion. For all types of analysis, statistically 
significant difference was p <0.05.
Findings
Our findings show that patients with proliferative fibrocystic disease of the 
breast (group 2)  had the highest concentration of luteinizing hormone (1  group: 
6.02 ± 0.13  nmol/l, 2  group: 13.06 ± 0.67  nmol/l, and 3  group: 5.82 ± 0.54  nmol/l) and 
follicle stimulating hormone (1 group: 3.86 ± 0.97 nmol/l, 2 group: 16.85 ± 3.21 nmol/l, 
and 3  group: 4.10 ± 0.16  nmol/l) and reduced concentration of estradiol (1  group: 
225.73 ± 22.34  pg/ml, 2  group: 66.94 ± 16.41  pg/ml, and 3  group: 196.57 ± 22.93  pg/ml) 
and progesterone (1 group: 8.07 ± 0.35 nmol/l, 2 group: 5.11 ± 0.7 nmol/l, and 3 group: 
16.48 ± 2.21 nmol/l). Moreover, the highest testosterone content was found in patients of 
group 1 (1.05 ± 0.09 ng/ml, p < 0.05 compared to groups 2 and 3) (Table 1).
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Luteinizing hormone (nmol/l) 6.02 0.13 13.06 ± 0.67* 5.20 ± 0.54
Follicle stimulating hormone 
(nmol/l) 3.85 ± 0.09 16.85 ± 3.22** 4.10 ± 0.16
Estradiol (pg/ml) 225.73 ± 22.37 86.94 ± 16.41** 196.57 ± 22.93
Progesterone (nmol/l) 8.07 ± 0.35* 5.11 ± 0.76** 16.48 ± 2.20
Prolactin (ng/ml) 8.8 ± 0.131 7.42 ± 0.48 7.35 ± 0.93
Cortisol (nmol/l) 457.31 ± 32.11 419.93 ± 15.49 432.32 ± 42.24
Testosterone (ng/ml) 1.05 ± 0.09* 0.69 ± 0.06 0.79 ± 0.13
Preliability relative to group 3 * < 0.05 and ** <0.01.
The specifics of menstrual dysfunction in the women examined were as follows: pa-
tients with a combination of hyperplastic processes of the mammary glands and uterus 
had ovulatory (33.3 %) or anovulatory (46.7 %) menstrual cycle or luteal phase insuffi-
ciency (20.0 %). Patients with proliferative fibrocystic disease of the breast had anovula-
tory (74.0 %) menstrual cycles or luteal phase insufficiency (26.0 %) (Table 2).
Table 2. The specifics of the menstrual dysfunction ( %)
Group 1 Group 2 Group 3
Regular menstrual cycle 73.3 – 33.3
Luteal phase insufficiency 26.7 26 20
Anovulatory cycle – 74 46.7
Women with regular ovulatory menstrual cycle typically had progesterone excre-
tion within the acceptable range, close to the lower limit, and high testosterone content 
(Table  3).




LH (nmol/l) 4.65 ± 0.53* 6.99 ± 0.28
FSH (nmol/l) 3.32 ± 0.40* 4.10 ± 0.23
LH/FSH 1.22 ± 0.12* 1.41 ± 0.08
Estradiol (pg/ml) 224.57 ± 23.34 234.90 ± 22.43
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Prolactin (ng/ml) 7.53 ± 0.90 9.41 ± 0.99
Cortisol (nmol/l) 488.30 ± 51.71* 728.67 ± 64.15
Testosterone (ng/ml) 0.94 ± 0.14* 0.56 ± 0.06
Preliability relative to group 3 * < 0.05 and ** <0.01.
In the presence of the luteal phase deficiency, hyperestrogenism, progesterone insuf-
ficiency and high levels of testosterone were observed.
Against the background of anovulatory menstrual cycle, an increased excretion of 
prolactin, within acceptable limits, was observed, as well as a high concentration of tes-
tosterone (Table 4).




LH (nmol/l) 4.65 ± 0.53 4.25 ± 0.53 2.75 ± 0.08
FSH (nmol/l) 4.60 ± 0.56 2.78 ± 0.63 3.63 ± 0.06
Estradiol (pg/ml) 221.12 ± 46.39 198.92 ± 20.66 82.56 ± 18.24
Progesterone (nmol/l) 7.60 ± 0.84 16.24 ± 2.22 1.35 ± 0.08
Prolactin (ng/ml) 7.33 ± 0.02 17.00 ± 1.65 4.95 ± 0.81
Cortisol (nmol/l) 422.09 ± 45.65 534.72 ± 25.37 386.254 ± 33.49
Testosterone (ng/ml) 0.95 ± 0.29 0.37 ± 0.02 1.42 ± 0.32
Preliability relative to group 3 * < 0.05 and ** <0.01.
Patients with luteal phase insufficiency typically had hyperprolactinemia and estra-
diol concentration at the upper limit of the normal range. Patients with proliferative fi-
brocystic disease of the breast and anovulatory menstrual cycle typically had hyperprol-
actinemia, an increase in the concentration of luteinizing hormone and follicle stimulat-
ing hormone with the predominance of the latter, low concentrations of progesterone and 
estradiol (Table 5).
Conclusions
The results show that a significant risk factor for hyperplastic processes of the mam-
mary glands and uterus in cases with regular ovulatory menstrual cycle is a decrease in 
the excretion of progesterone and cortisol, as well as an increase in the concentration of 
testosterone. 
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Against the background of menstrual cycle disorders in the form of luteal phase in-
sufficiency, the risk factor is an increase in the concentration of estradiol in the context 
of progesterone insufficiency and testosterone hyperproduction. A risk factor for prolif-
erative fibrocystic disease of the breast is hyperprolactinemia in the presence of hypere-
strogenism. A risk factor for hyperplastic processes of the mammary glands and uterus 
in cases of anovulatory menstrual cycle is hyperprolactinemia in the presence of testos-
terone hyperproduction. A risk factor for proliferative fibrocystic disease of the breast is 
hyperprolactinemia with an increase in the concentration of follicle stimulating hormone 
against the background of hypestrogenism and progesterone insufficiency.
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